Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 10/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22491519 | 0.88 | MGLL (0.51) | NR3C2MGLLLMNAALDH1A1GAA | |
| SCHEMBL29734572 | 0.88 | MGLL (0.51) | NR3C2MGLLLMNAALDH1A1GAA | |
| SCHEMBL531974 | 0.83 | PARP1 (0.62) | NR3C2MGLLLMNAALDH1A1GAA | |
| SCHEMBL22491570 | 0.80 | ALDH1A1 (0.53) | NR3C2MGLLLMNAALDH1A1GAA | |
| SCHEMBL22491346 | 0.80 | NR3C2 (0.49) | NR3C2MGLLLMNAALDH1A1GAA | |
| SCHEMBL29734574 | 0.80 | NR3C2 (0.49) | NR3C2MGLLLMNAALDH1A1GAA | |
| SCHEMBL30541695 | 0.79 | MGLL (0.54) | NR3C2MGLLLMNAALDH1A1GAA | |
| SCHEMBL21061846 | 0.79 | MGLL (0.54) | NR3C2MGLLLMNAALDH1A1GAA | |
| SCHEMBL30541688 | 0.78 | NR3C2 (0.56) | NR3C2MGLLLMNAALDH1A1GAA | |
| SCHEMBL21097482 | 0.78 | NR3C2 (0.56) | NR3C2MGLLLMNAALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-12-17 | — | — | US | claimed |
| EP-3717477-A1 | NEW HETEROCYCLIC COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2020-10-07 | — | — | EP | claimed |
| US-11420961-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2022-08-23 | — | — | US | disclosed |
| EP-3717477-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-07-20 | — | — | EP | disclosed |
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-12-17 | — | — | US | disclosed |
| EP-3717477-A1 | NEW HETEROCYCLIC COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420961-B2 | Heterocyclic compounds | LPXN, MLX, CCNY | NR3C2 2484/4885MGLL 1532/4885LMNA 16/4885 |
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | LPXN, MLX, CCNY | NR3C2 2484/4885MGLL 1532/4885LMNA 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.